Mesoblast Limited (MESO)

Market Cap	2.29B +23.4%
Revenue (ttm)	120.25M +599.2%
Net Income	-57.50M
EPS	-0.04
Shares Out	1.30B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,739
Open	17.81
Previous Close	18.18
Day's Range	17.33 - 18.08
52-Week Range	12.66 - 21.50
Beta	0.81
Analysts	Buy
Price Target	37.00 (+112.16%)
Earnings Date	Aug 26, 2026

About MESO

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative coli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO
• Website: https://www.mesoblast.com

Financial Performance

In fiscal year 2026, Mesoblast's revenue was $120.25 million, an increase of 599.21% compared to the previous year's $17.20 million. Losses were -$57.50 million, -43.71% less than in 2025.

Analyst Summary

According to 3 analysts, the average rating for MESO stock is "Buy." The 12-month stock price target is $37.0, which is an increase of 112.16% from the latest price.

Price Target

$37.0

(112.16% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 29, 2026

Data Sources Report a data error